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Abstract
Thrombotic microangiopathy (TMA) is a rare, but potentially lethal condition requiring rapid recognition, diagnosis and 
initiation of therapy. Here, we present two cases of women with hemolytic anemia, thrombocytopenia and acute kidney 
injury shortly after surgical termination of pregnancy. Histological examination of their kidneys revealed endothelial cell 
swelling and luminal stenosis or fibrin‑containing thrombi in the glomeruli and arterioles, which support the diagnosis of 
TMA. The patients were treated with hemodialysis, plasma infusion and corticosteroids with or without immunosuppressive 
agents. Three weeks after treatment, one patient was cured and symptoms of the other patient markedly improved. 
Reporting of more cases of TMA associated with surgical termination of pregnancy will provide further insights into this 
rare disease, possibly aiding in identifying risk factors and improving time to clinical diagnosis, treatment and prognosis.
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Introduction
Thrombotic microangiopathy (TMA), a rare and 
life‑threatening syndrome, is characterized by hemolytic 
anemia (HA) with schistocytes and thrombocytopenia 
associated with variable signs of organ injury due to platelet 
thrombi in the microcirculation.[1,2] Several potential causes, 
including autoimmune disorders, infections, transplantation, 
malignancy, medications, anti‑phospholipid syndrome and 
pregnancy, have been identified.[3]
TMA occurs with increased frequency during or in relation 
to pregnancy. It has been reported to occur in 1 in 25,000 
pregnancies.[4,5] Pregnancy‑associated TMA typically 
occurs during late pregnancy, especially the second and 
early third trimesters.[6,7] Cases of TMA associated with 
induced abortion in the first trimester of pregnancy are rarely 
reported and are poorly understood.[3,8] There has only been 
one case report from Japan describing a Russian woman with 
systemic lupus erythematosus, anti‑phospholipid syndrome 
and renal failure at 14 weeks of pregnancy, who developed 
TMA shortly after surgical abortion.[8] However, cases of 
TMA associated solely with induced abortions have not 
been reported. Here, we present two unusual cases of 
women with TMA diagnosed in close relation to termination 
of pregnancy in the first trimester. These patients were 
treated with hemodialysis, infusion of plasma and high‑dose 
corticosteroids with or without immunosuppressive agents. 
After treatment, one patient was cured and the symptoms 
associated with the other patient were markedly attenuated.
Case Reports
Case 1
A 41‑year‑old woman was admitted to our hospital with a 
3‑h history of vaginal bleeding due to taking mifepristone 
orally after a 12‑week pregnancy. At the beginning of 
pregnancy, she had taken ethinylestradiol and cyproterone 
acetate tablets orally for 21 days to promote contraception. 
There was no history of chronic diseases. Obstetric history 
included six abortions and two live births. Suction dilation 
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and curettage were performed after admission because of 
the quantity of vaginal bleeding due to expulsion of the 
embryo and placental tissue. The quantity of decidua tissue 
and cruor was measured to 300 ml.
On the first post‑operative day, patient had fatigue, 
headache and oliguria and was confused and disoriented. 
The hemoglobin level declined from 107 g/L pre‑operatively 
to 73 g/L post‑operatively. The laboratory findings [Table 1] 
indicated that patient had anemia, thrombocytopenia, 
renal failure, proteinuria, microscopic hematuria, urinary 
siderosis, elevated reticulocyte and serum L‑lactate 
dehydrogenase (LDH) levels and more importantly, 
schistocytosis; all these findings supported the TMA diagnosis. 
Meanwhile, her anti‑cardiolipin antibodies, anti‑nuclear 
antibodies, anti‑double stranded deoxyribonucleic 
acid (DNA) antibodies, myeloperoxidase anti‑neutrophil 
cytoplasmic autoantibodies, (MPO‑ANCAs) proteinase‑3 
anti‑neutrophil cytoplasmic autoantibodies, (PR3‑ANCAs) 
anti‑glomerular basement membrane (GBM) antibody, 
Coombs test and Ham test were all negative.
Renal biopsy on the 12 day of hospitalization revealed 
segmental proliferation of mesangial cells and matrix in 
the glomeruli, diffuse vacuolar degeneration of cells in 
the tubules and intima mucoid edematous thickening 
and endothelial cell swelling with lumenal stenosis in 
the arterioles [Figure 1a]. Fibrin thrombi were not found 
in the glomeruli or arterioles. No immune deposits were 
shown by electron microscopy or by immunofluorescence 
microscopy.
Patient was diagnosed with TMA and acute renal failure. 
Hemodialysis and plasma infusion were initiated while she 
was given pulse hexadecadrol (10 mg/day, three doses) and 
oral prednisolone (1 mg/kg). Three weeks after corticosteroid 
treatment, laboratory investigations showed renal function, 
platelet count, red blood cell number, hemoglobin level and 
LDH level recovered to normal levels and there were no 
schistocytes in the peripheral blood smear.
Case 2
A 38‑year‑old woman was admitted to our hospital with 
a 3‑day history of edema and anuria. Medical history 
Table 1: Laboratory data from the two patients in the study
Laboratory tests Case 1 Case 2 Normal value
At admission Post‑treatment At admission Post‑treatment
RBC, 1012/L 3.03 3.77 2.97 2.54 3.50‑5.00
Hb, g/L
Pre‑operative 107 114 126 71 110‑150
Post‑operative 73 67
WBC, 109/L 7.3 9.3 10.7 9.8 4‑10
PLT, 109/L 58 147 83 200 100‑300
Hematocrit, L/L 0.217 0.35 0.215 0.23 0.370‑0.480
Reticulocytes, 1012/L 0. 11 0.09 0.13 0.04 0.0224‑0.0829
Creatinine, mmol/L 359.6 72.1 717.1 291.9 44.0‑115.0
BUN, mmol/L 13.02 7.58 27.15 9.61 3.20‑7.00
LDH, U/L 421 190 2147 291 135‑226
Indirect bilirubin, mmol/L 26.4 9.1 12.5 5 5.1‑21.4
Serum total protein, g/L 47.7 60.3 45.4 53.4 60.0‑83.0
Serum albumin, g/L 23.6 35.7 25.1 29.9 35.0‑55.0
Urinary proteinuria + ‑ 3+ + ‑
Urinary occult blood 3+ ‑ 3+ 3+ ‑
Urinary sediments RBC per high‑power field 0.5 0.5 608.2 6.7 0.0‑5.0
Urinary protein excretion, g/day 0.09 0.10 No data No data <0.20
Urinary siderosis + + + + ‑
Serum C3, g/L 0.748 0.10 0.80 0.12 0.90‑1.80
Serum C4, g/L 0.17 0.30 0.14 0.40 0.10‑1.40
Peripheral blood smear Schistocytes ‑ Schistocytes ‑ ‑
BUN=Blood urea nitrogen; C=Complement; Hb=Hemoglobin; LDH=L‑lactate dehydrogenase; PLT=Platelet; RBC=Red blood cell; WBC=White blood cell
Figure 1: Histological findings of renal biopsy specimens (a) Light 
micrograph of the renal biopsy from the patient in Case 1, showing 
endothelial cell swelling and lumenal stenosis in the arterioles (arrow) 
H and E, ×400. (b) Light micrograph of the renal biopsy from the 
patient in Case 2, showing fibrin thrombi in the glomeruli (arrows) 
Masson trichrome stain, ×400. (c) Light micrograph of the renal 
biopsy from the patient in Case 2, showing fibrin thrombi in the 
glomeruli and arterioles (arrows) Masson trichrome stain, ×40
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review revealed that patient had had suction dilation and 
curettage 9 days ago for an induced abortion after an 8‑week 
pregnancy. The day after the operation, hemoglobin declined 
from 126 g/L pre‑operatively to 77 g/L post‑operatively 
and platelets declined from 220 × 109/L pre‑operatively 
to 47 × 109/L post‑operatively. There was no remarkable 
history of chronic diseases. Obstetric history included one 
live birth. At admission, the patient suffered from abdominal 
pain, nasal hemorrhage and edema and her urinary volume 
was only 40 ml/day. Physical examination revealed a body 
temperature of 38°C, severe anemia and edema.
The laboratory findings [Table 1] indicated that the 
patient had anemia, thrombocytopenia, renal failure, 
proteinuria, microscopic hematuria, urinary siderosis, 
elevated reticulocyte and serum LDH levels and more 
importantly, schistocytosis. Meanwhile, her anti‑cardiolipin 
antibodies, anti‑nuclear antibodies, anti‑double stranded 
DNA ant ibodies ,  MPO ‑ANCAs,  PR3‑ANCAs, 
anti‑GBM antibody, Coombs tests and Ham test were all 
negative. Renal biopsy on the 2nd day of hospitalization 
revealed fibrin thrombi in the glomeruli [Figure 1b] and 
arterioles [Figure 1c] in the absence of immune deposits, 
which is characteristic of TMA. Electron microscopy 
showed no electron‑dense deposit.
She was diagnosed with TMA and acute kidney injury. 
Hemodialysis and plasma infusion were initially performed. 
Meanwhile, she was given a bolus of methylprednisolone 
(500 mg/day, three doses) and cyclophosphamide 
(0.6 g/day, 1 dose/month). Patient then continued on oral 
prednisolone (1 mg/kg/day). Three weeks after corticosteroid 
treatment, edema and anuria were corrected. Laboratory 
investigations showed renal function, platelet count, red 
blood cell count and hemoglobin levels improved. LDH 
recovered to normal levels and there were no schistocytes 
in the peripheral blood smear.
Discussion
TMA is a rare, but serious disorder that is associated with 
anemia and significant organ failure due to the deposition 
of fibrin and platelet thrombi in the microcirculation.[9] 
Pregnancy is one of the common precipitating events for 
TMA. This is thought to be due to the association of 
pregnancy with increasing concentrations of procoagulant 
factors, decreasing fibrinolytic activity, loss of endothelial cell 
thrombomodulin and changes of hormones.[4,5] Interestingly, 
anemia and even thrombocytopenia emerged in both cases 
shortly after surgical termination of pregnancy. TMA is 
believed to manifest from endothelial dysfunction, but the 
mechanistic relationship between TMA and termination of 
pregnancy in the present cases is unknown. It is unlikely that 
the operation by itself triggered the onset of TMA. Rather, 
decreasing human chorionic gonadotropin (HCG) levels 
after termination of pregnancy, possibly in synergy with 
endothelial and hemostasis dysfunction, may have caused 
a predisposition for development of TMA.
It was challenging to make a correct diagnosis for 
TMA in the present cases. The following set of five 
signs and symptoms has been associated with TMA: 
thrombocytopenia, microangiopathic HA, neurological 
abnormalities, renal failure and fever.[6,7] The diagnostic 
laboratory features of TMA in pregnancy are identical 
to those in the non‑pregnant state, which include 
anemia and thrombocytopenia. Evidence of red cell 
fragmentation (schistocytes and polychromasia) should 
be sought on the peripheral blood smear; elevated LDH 
and indirect hyperbilirubinemia are also commonly seen. 
A negative direct Coomb’s test is necessary to exclude 
autoimmune HA.[10]
The diagnosis of TMA was confirmed by renal biopsy. In 
TMA, glomerular endothelial damage leads to the formation 
of microthrombi within the glomerular capillaries and 
subsequent endothelial cell proliferation, thickening of the 
basement membrane and formation of double contours.[11] 
In the first case, we did not have prior experience with 
the diagnosis of TMA and there was a delay of 12 days for 
the renal biopsy. The second case, in contrast, featured 
an immediate renal biopsy due to prior experience in 
the diagnosis. In the first case, although fibrin thrombi 
and double contours were not found in the glomeruli or 
arterioles, intima mucoid edematous thickening, endothelial 
cell swelling in the arterioles, and luminal stenosis of 
arterioles were observed, which were consistent with TMA. 
In the second case, renal biopsy revealed fibrin thrombi 
in the glomeruli and arterioles in the absence of immune 
deposits, which is characteristic of TMA.
At present, the most effective therapeutic regimen for acute 
TMA is plasma exchange or infusion due to complement 
dysregulation.[12] Although plasma exchange had not 
been carried out in our patients, hemodialysis and plasma 
infusion were shown to be effective. Meanwhile, several 
trials suggested that the administration of high‑dose steroids 
improves clinical outcomes.[12‑14] Hence, corticosteroids 
were given in the present cases. Other trials have suggested 
that cyclophosphamide provides comparably high remission 
rates in severe TMA with acceptable side‑effects and should 
be considered in the more severe patients.[15] Patient in Case 
2 was given cyclophosphamide because of the severity of 
symptoms and kidney injury. After 3 weeks of treatment, 
one patient was cured and the other patient’s symptoms 
were markedly improved.
Conclusion
The present cases show that TMA may be associated 
with termination of pregnancy. An accurate diagnosis of 
TMA is challenging when symptoms occur in women after 
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termination of pregnancy. More reports of TMA in patients 
with pregnancy will likely provide further insights into 
the pathogenesis of this rare disease, possibly uncovering 
underlying mechanisms to aid in early diagnosis and 
development of effective therapies.
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